<SEC-DOCUMENT>0001104659-24-117773.txt : 20241113
<SEC-HEADER>0001104659-24-117773.hdr.sgml : 20241113
<ACCEPTANCE-DATETIME>20241113163456
ACCESSION NUMBER:		0001104659-24-117773
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241113
DATE AS OF CHANGE:		20241113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Transcode Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001829635
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811065054
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40363
		FILM NUMBER:		241455006

	BUSINESS ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		857-301-6857

	MAIL ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2428266d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Wingdings">x</FONT>
Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TransCode Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">No fee required. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2428266d1_defa14aimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Open Letter to Shareholders&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Shareholders,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At our upcoming Special Meeting to be held November 22, shareholders
are being asked to authorize our Board of Directors to effect a reverse split &ndash; only if the Board determines that doing so is necessary
as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many shareholders rightly ask why this request. Some believe that the
potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is
no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reverse split is NOT something directors or management wishes to
do &ndash; we all hope it won&rsquo;t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing
did so on the condition that our shareholders authorize a reverse split &ndash; should one be necessary. The reverse split will not be
necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our stock does not meet this Nasdaq requirement, and we do not have
your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse
effect on the value of our company and the value of your stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our assessment boils down to this: your vote is your decision about
whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue
the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TransCode&rsquo;s management and directors are unanimously determined
to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to
implement this decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We call for your understanding and greatly appreciate your support.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your Board and Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal; text-transform: uppercase">TransCode
Therapeutics, Inc.&bull; 6 Liberty Square #2382 &bull; Boston, MA 02109</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2428266d1_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2428266d1_defa14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  7,# 2(  A$! Q$!_\0
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MX=!57^TK3_GK_P".G_"IYO\ 4R?[I_E7FW@CPWI>M:;<S7T#22)-L4B1EP,
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M_P#A ?#W_/K)_P!_F_QIWB7PU<ZW>V5U;7BVTEKDJ2F[G((/Z57_ +"\4_\
M0RC_ +\"M+Z*S(MJ[HF_X0'P]_SZR?\ ?YO\:V=+TJTT>T^RV2%(MQ;!8MR?
MK]*P/["\4_\ 0RC_ +\"MW2+6^M++RM0O/M<^\GS-NWCTQ4MNVXU:^Q?HHHJ
M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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CTJ**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
